Gepirone (INN) (current developmental code name TGFK07AD; proposed brand name Travivo) or gepirone hydrochloride (USAN) is an antidepressant and anxiolytic drug of the azapirone group that was synthesized by Bristol-Myers Squibb in 1986 and has been under development for the treatment of depression but has yet to be marketed. Like other azapirones, it acts as a selective partial agonist of the 5-HT1A receptor. Gepirone has been under development in the U.S. in an extended release form (referred to as gepirone ER), but despite completing phase III clinical trials and demonstrating efficacy, it has been rejected multiple times by the FDA during the drug approval process.

CAS：83928-76-1
中文别名：
英文别名：4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione;
分子式：C19H29N5O2
分子量：359.466
精确质量：359.232
Psa：69.64
Logp：1.4948

MDL号：MFCD00868196

密度：1.1±0.1g/cm3
沸点：562.3±60.0°Cat760mmHg
闪点：293.8±32.9°C
蒸汽压：0.0±1.5mmHgat25°C
折射率：1.542
储存条件：2-8°C，保存于惰性气体中

海关编码：2933990090